Follow the Valeant Pharmaceuticals International, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 28 January 2016 (Retenue fiscale). Among the most active insiders: Kellen Ari. All data is accessible without an account.
6
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Valeant Pharmaceuticals International, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 26,674 of 28,901 companies
19.2
score / 100
Value
23
Quality
16
FCF yld-4.0%
Earn yld-5.1%
EV/EBITDA·
ROE-40%
Gross mgn·
Net mgn-1.3%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,506 sharesCommon Stock, no par valueSEC:0000885590-16-000084:0
6 of 6 declarations
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company focused on the development and commercialization of drugs. It is listed on NASDAQ under the symbol VRX.